Add RYTM to watchlist(s)

You Should Create a Watchlist In The First Place.

Profile

Company Name

Rhythm Pharmaceuticals, Inc.

Symbol

RYTM

Currency

USD

Exchange

Nasdaq

Head Quarter

United States, Boston

Sector

Healthcare

Industry

Biotechnology

Website

https://www.rhythmtx.com

ISIN

US76243J1051

CIK

1649904

CUSIP

76243J105

UEI

LEI

Business Description

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc.